0000849636 false 0000849636 2022-09-07 2022-09-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549




Current Report


Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): September 7, 2022



(Exact name of registrant as specified in its charter)


Delaware   1-16467   33-0303583

(State or other jurisdiction

of incorporation)



File Number)


(I.R.S Employer

Identification No.)


126 Valley Road, Suite C

Glen Rock, New Jersey

(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code: (201) 444-4947



(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐







Item 7.01. Regulation FD Disclosure.


ResolutionRx, the pharmaceutical cannabinoid business unit of RespireRx Pharmaceuticals Inc. (the “Company”), participated in the 5th International Cannabinoid-Derived Pharmaceuticals Summit, which took place September 7-8, 2022 in Boston, MA. As an invited guest speaker, Arnold S. Lippa, Ph.D., the Company’s Interim President, Interim Chief Executive Officer, and Chief Scientific Officer presented a talk (“Presentation Materials”) entitled “Drug Re-purposing: A Case Study of Dronabinol”, in which he described the advantages of re-purposing an already FDA approved drug for a new therapeutic indication, using our development program for dronabinol as an example. Dr. Lippa reviewed the clinical and operational programs completed to date and then focused on our new lipid-based nanotechnology formulation for dronabinol that is intended to create a superior approach to administering oral dronabinol as well as extend and solidify our intellectual property base. During the summit, he also participated in meetings with third parties.


The information in this Item 7.01 and the document attached as Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.


Item 9.01 Financial Statements and Exhibits


(d) Exhibits.


Exhibit Number   Exhibit Description
99.1   RespireRx-ResolutionRx Slide Presentation
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: September 13, 2022



  By: /s/ Jeff E. Margolis

Jeff E. Margolis

    SVP, CFO, Secretary and Treasurer




RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more RespireRx Pharmaceuticals (PK) Charts.
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more RespireRx Pharmaceuticals (PK) Charts.